Evolent Health, Inc (NYSE:EVH) CEO Steve Wigginton sold 6,000 shares of Evolent Health stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $25.07, for a total value of $150,420.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Steve Wigginton also recently made the following trade(s):
- On Tuesday, June 6th, Steve Wigginton sold 959 shares of Evolent Health stock. The shares were sold at an average price of $25.75, for a total value of $24,694.25.
- On Monday, May 1st, Steve Wigginton sold 6,000 shares of Evolent Health stock. The shares were sold at an average price of $23.10, for a total value of $138,600.00.
Evolent Health, Inc (NYSE:EVH) traded down 1.36% on Monday, hitting $25.30. The stock had a trading volume of 72,764 shares. The firm’s market cap is $1.46 billion. The company has a 50-day moving average price of $25.04 and a 200 day moving average price of $21.05. Evolent Health, Inc has a 52-week low of $14.50 and a 52-week high of $27.50.
Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Tuesday, May 9th. The technology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.11. Evolent Health had a negative net margin of 17.69% and a negative return on equity of 7.06%. The business had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $104.38 million. During the same quarter in the prior year, the company posted ($0.16) EPS. The business’s revenue for the quarter was up 116.2% on a year-over-year basis. Equities analysts forecast that Evolent Health, Inc will post ($0.41) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.wkrb13.com/markets/2285429/steve-wigginton-sells-6000-shares-of-evolent-health-inc-nyseevh-stock.html.
Several hedge funds have recently modified their holdings of the stock. US Bancorp DE raised its stake in shares of Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock valued at $126,000 after buying an additional 19 shares in the last quarter. Point72 Asia Hong Kong Ltd acquired a new stake in shares of Evolent Health during the first quarter valued at approximately $126,000. Bank of Montreal Can raised its stake in shares of Evolent Health by 4,249.7% in the first quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock valued at $138,000 after buying an additional 6,077 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Evolent Health by 286.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,744 shares of the technology company’s stock valued at $150,000 after buying an additional 5,000 shares in the last quarter. Finally, Pacad Investment Ltd. acquired a new stake in shares of Evolent Health during the fourth quarter valued at approximately $165,000. Hedge funds and other institutional investors own 68.48% of the company’s stock.
A number of research analysts have issued reports on the company. Robert W. Baird reiterated an “outperform” rating and set a $35.00 price objective (up previously from $30.00) on shares of Evolent Health in a research note on Wednesday, June 14th. TheStreet upgraded Evolent Health from a “d” rating to a “c-” rating in a research note on Monday, May 22nd. Jefferies Group LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Evolent Health in a research note on Thursday, April 13th. Leerink Swann reiterated an “outperform” rating and set a $32.00 price objective (up previously from $30.00) on shares of Evolent Health in a research note on Monday, June 19th. Finally, Oppenheimer Holdings, Inc. assumed coverage on Evolent Health in a research note on Monday, March 13th. They set an “outperform” rating and a $28.00 price objective for the company. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Evolent Health currently has a consensus rating of “Buy” and a consensus price target of $29.73.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285429/steve-wigginton-sells-6000-shares-of-evolent-health-inc-nyseevh-stock.html
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.